New hope for tough cancer: drug combo trial seeks to control advanced pancreatic disease
NCT ID NCT07259317
Summary
This study is testing whether adding an oral drug called relacorilant to two standard chemotherapy drugs can help control advanced pancreatic cancer that has spread. It will involve about 60 adults whose cancer has not yet been treated. The main goal is to see if this three-drug combination is safe and can slow down the cancer's progression for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, PANCREATIC DUCTAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site 01
RECRUITINGSan Antonio, Texas, 78229, United States
-
Site 02
RECRUITINGScottsdale, Arizona, 85258, United States
-
Site 03
RECRUITINGGrand Rapids, Michigan, 49503, United States
-
Site 04
RECRUITINGLos Angeles, California, 90025, United States
Conditions
Explore the condition pages connected to this study.